The company's cash runway into Q2 2028 provides a buffer, but the lack of revenue and reliance on strategic alternatives (partnerships, M&A) for value creation means the stock will move on news of any such transaction or pipeline advancement. Monitor for updates on SGX945 (dusquetide) for Behçet's disease and any Nasdaq compliance developments.
Drugs in focus
SNGX drug pipeline →SGX945
● Neutral Named in this press release- Impact
- Phase
- Phase 2
- Time to market
- At least 3-5 years away, assuming a successful Phase 2b/3 program is initiated and completed. The company has not announced a registrational trial start date and may need a partner to fund it.
- Next catalyst
- None dated
What to watchWatch for any announcement from Soligenix regarding the next development steps for SGX945, including potential Phase 3 trial plans or a partnership/licensing deal. The company is actively evaluating strategic alternatives, so any M&A or partnership news could be a major catalyst. Also monitor for any new clinical trial initiations or regulatory milestone updates.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $0.3350entry
- T+1 · 8d ago +2.03%α −0.34% · $0.3418
- T+5 · 4d ago −4.18%α −6.77% · $0.3210
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Soligenix reported a net loss of $1.1M ($0.05 per share) for Q3 2026, narrower than the $2.5M loss in Q3 2025, driven by lower R&D spending after the FLASH2 trial termination. The company had $9.0M in cash, expected to fund operations into Q2 2028, and is evaluating strategic alternatives including partnerships, M&A, and licensing. The EPS of -$0.05 beat the consensus estimate of -$0.09.
Key Financial Metrics
Key Facts
- Net loss of $1.1M ($0.05 per share) for Q3 2026 vs $2.5M ($0.58 per share) in Q3 2025
- No revenue for Q3 2026 or Q3 2025
- Cash and cash equivalents of $9.0M as of September 30, 2026
- Cash runway expected into Q2 2028
- R&D expenses decreased to $0.4M from $1.6M due to FLASH2 trial termination
- G&A expenses flat at $1.0M
- Company evaluating strategic alternatives including partnership, licensing, M&A, and government grants
Financial Impact
Net loss improved by $1.4M YoY; cash position $9.0M
Risk Factors
- No revenue and reliance on strategic alternatives for stockholder value
- Nasdaq listing compliance risk (minimum bid price requirement)
- Going concern risk if financing or strategic transactions are not secured
- Terminated FLASH2 trial and HyBryte development program
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302931171 |
Track record
7 reports on SNGX
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +69.30% at T+20 after the Apr 3, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 6, 202610d ago Press Release Neutral 4/10 Viewing Entry $0.3350 Now $0.2900 −13.43% settles Feb 4
- Nov 2, 202614d ago SC 13G/A Neutral 2/10 Entry $0.3612 Now $0.2900 −19.71% settles Jan 29
- Jun 26, 202620w ago 8-K Bearish 6/10 Entry $0.4000 to $0.3850 Now $0.2900 +27.50% ▲ +3.75% +8.14% vs SPY
- Jun 26, 202620w ago 424B5 Bearish 7/10 Entry $0.4000 to $0.3850 Now $0.2900 +27.50% ▲ +3.75% +8.14% vs SPY
- May 28, 202624w ago 8-K Bearish 5/10 Entry $0.9100 to $0.4047 Now $0.2900 +68.13% ▲ +55.53% +56.71% vs SPY
- May 28, 202624w ago 424B5 Bearish 6/10 Entry $0.9100 to $0.4047 Now $0.2900 +68.13% ▲ +55.53% +56.71% vs SPY
- Apr 3, 202632w ago EFFECT Bearish 6/10 Entry $1.14 to $0.3970 Now $0.2900 +74.56% ▲ +65.18% +78.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers